LEGN Legend Biotech
- 45.960
- +0.660+1.46%
Legend Biotech News
Analysts Offer Insights on Healthcare Companies: Legend Biotech (LEGN), Astria Therapeutics (ATXS) and Aslan Pharmaceuticals (ASLN)
Express News | HC Wainwright & Co. Reiterates Buy on Legend Biotech, Maintains $87 Price Target
Legend Biotech Analyst Ratings
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 04/23/2024 84.87% HC Wainwright & Co. → $87 Reiterates Buy → Buy 04/17/2024 38.12% Scotiabank $65 → $65 Up
Genscript Biotech Unit Gets Approval for Blood Cancer Drug by European Commission
Genscript Biotech's (HKG:1548) unit Legend Biotech has received approval from the European Commission for CARVYKTI to treat adult patients with relapsed and refractory multiple myeloma, the biotechnol
Johnson & Johnson (JNJ.US) & Legendary Biotech's CAR-T Therapy Receives EU Approval Again
In December 2017, Johnson & Johnson Innovative Pharmaceuticals, a subsidiary of Johnson & Johnson, signed an exclusive global license and cooperation agreement with Legendary Biotech to develop and commercialize Sidakiolene.
Kingsley Biotech (01548): Legendary Biotech announced that the European Commission approved CARVYKTI for second-line treatment of patients with recurrent refractory multiple myeloma
Kingsley Biotech (01548) announced that Legend Biotech, a non-wholly-owned subsidiary of the company, was released in 2024...
Hold Rating on Legend Biotech Amidst Approval of Carvykti and Commercial Manufacturing Challenges
European Approval for Legend Biotech's Myeloma Treatment
Legend Biotech's Carvykti Gets European Commission Approval for Treatment of Blood Cancer
Legend Biotech (LEGN) said Monday its medicine Carvykti was approved in Europe as a second line treatment for a type of blood cancer. The European Commission's approval covers the treatment's use in a
Express News | Carvykti® (Ciltacabtagene Autoleucel) Approved by the European Commission for Second-Line Treatment of Patients With Relapsed and Refractory Multiple Myeloma
FDA Mandates "Boxed Warning" For Bristol Myers, Johnson & Johnson CAR-T-Based Blood Cancer Therapies
Following an investigation announced in November last year, the FDA said on Thursday that it would now require boxed warnings—the highest safety-related caution for medications—for all chimeric antige
FDA Requires Labeling Changes to CAR-T Cell Therapies to Reflect Cancer Risk
Scotiabank Upgrades Legend Biotech to Sector Outperform
Analyst Ratings For Legend Biotech
12 analysts have expressed a variety of opinions on Legend Biotech (NASDAQ:LEGN) over the past quarter, offering a diverse set of opinions from bullish to bearish.The following table summarizes their
Express News | Scotiabank Upgrades Legend Biotech to Sector Outperform, Maintains Price Target to $65
Express News | Legend Biotech Corp : Scotiabank Raises to Sector Outperform From Sector Perform
Genscript Biotech's Unit Logs $157 Million in Q1 Sales of Blood Cancer Drug
Genscript Biotech's (HKG:1548) unit Legend Biotech recorded $157 million in net trade sales of its blood cancer drug CARVYKTI in the first quarter of 2024, a Tuesday filing on the Hong Kong bourse sai
The CAR-T market is approaching 100 billion dollars: domestic companies ensure “survival”, and multinational companies earn dollars
On March 1 of this year, Keji Pharmaceutical-B (02171)'s CAR-T therapy Zewokie Orense injection (SAKIZE) was officially approved for sale, and the number of CAR-T treatments marketed worldwide has also reached 11. Although some of these products compete with each other in terms of treatment of indications, the rapid growth in sales of leading products is still driving the rapid expansion of the global market. The Zhitong Finance App learned that the global CAR-T cell therapy market is expected to reach US$88.52 billion in 2032. The 100 billion dollar market is in sight, and it continues to boost the market's investment confidence. However, not every product
Kingsley Biotech: CARVYKTI's net trade sales in the first quarter were about US$157 million
Kingsley Biotech (01548) issued an announcement. On April 16, 2024, Legend Biotechnology Co., Ltd. (Legend Biotech) announced that according to Legend Biotech and Janssen Biotech, Inc. (Janssen) signed a cooperation and licensing agreement on December 21, 2017
Analysts Are Bullish on These Healthcare Stocks: Legend Biotech (LEGN), Genmab (GMAB)
Analysis
Price Target
No Data
